A Long-term Response to Nivolumab in a Case of PD-L1-negative Lung Adenocarcinoma with an EGFR Mutation and Surrounding PD-L1-positive Tumor-associated Macrophages

Anti-programmed cell death 1 (PD-1) antibodies have poor efficacy in epidermal growth factor receptor (EGFR)-mutated lung cancer. We herein report a 72-year-old man with programmed cell death-ligand 1 (PD-L1)-negative lung adenocarcinoma harboring an EGFR mutation that responded to nivolumab for mor...

Descripción completa

Detalles Bibliográficos
Autores principales: Watanabe, Hiromi, Ohashi, Kadoaki, Nishii, Kazuya, Seike, Keisuke, Makimoto, Go, Hotta, Katsuyuki, Maeda, Yoshinobu, Kiura, Katsuyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6859382/
https://www.ncbi.nlm.nih.gov/pubmed/31292383
http://dx.doi.org/10.2169/internalmedicine.2875-19

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6859382/
https://www.ncbi.nlm.nih.gov/pubmed/31292383
http://dx.doi.org/10.2169/internalmedicine.2875-19

Ejemplares similares